Deep vein thrombosis and pulmonary embolism in cirrhotic patients: Systematic review

World Journal of Gastroenterology

Volumn 20, Issue 19, 2014, Pages 5737-5745

  Aggarwal, Ashish ^a   Puri, Kanika ^a   Liangpunsakul, Suthat ^b  

^a INDIANA UNIVERSITY   (United States)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anticoagulation; Chronic liver disease; Cirrhosis; Deep venous thrombosis; Pathogenesis; Portal vein thrombosis; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; ENOXAPARIN; HEPARIN; PROTEIN C; PROTEIN S; VON WILLEBRAND FACTOR; THROMBIN;

ARTICLE; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; LUNG EMBOLISM; META ANALYSIS (TOPIC); PORTAL VEIN THROMBOSIS; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SYSTEMATIC REVIEW; THROMBOCYTE DISORDER; THROMBOCYTOPENIA; VITAMIN K DEFICIENCY; CHEMISTRY; COMPLICATION; DISEASE COURSE; FIBROSIS; HEMORRHAGE; LIVER; PATHOLOGY; PATHOPHYSIOLOGY; PORTAL VEIN; VEIN THROMBOSIS;

ANTICOAGULANTS; DISEASE PROGRESSION; FIBROSIS; HEMORRHAGE; HUMANS; LIVER; PORTAL VEIN; PREVALENCE; PULMONARY EMBOLISM; RISK FACTORS; THROMBIN; VENOUS THROMBOSIS;

EID: 84901236365     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i19.5737     Document Type: Article

References (55)

1. Tripodi A, Anstee QM, Sogaard KK, Primignani M, Valla DC. Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost 2011; 9: 1713-1723 [PMID: 21729237 DOI: 10.1111/j.1538-7836.2011.04429.x]
2. Tsochatzis EA, Senzolo M, Germani G, Gatt A, Burroughs AK. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther 2010; 31: 366-374 [PMID: 19863496 DOI: 10.1111/j.1365-2036.2009.04182.x]
3. Ponziani FR, Zocco MA, Garcovich M, D'Aversa F, Roccarina D, Gasbarrini A. What we should know about portal vein thrombosis in cirrhotic patients: a changing perspective. World J Gastroenterol 2012; 18: 5014-5020 [PMID: 23049208 DOI: 10.3748/wjg.v18.i36.5014]
4. John BV, Konjeti R, Aggarwal A, Lopez R, Atreja A, Miller C, Zein NN, Carey WD. Impact of untreated portal vein thrombosis on pre and post liver transplant outcomes in cirrhosis. Ann Hepatol 2013; 12: 952-958 [PMID: 24114826]
5. Gulley D, Teal E, Suvannasankha A, Chalasani N, Liangpunsakul S. Deep vein thrombosis and pulmonary embolism in cirrhosis patients. Dig Dis Sci 2008; 53: 3012-3017 [PMID: 18443906 DOI: 10.1007/s10620-008-0265-3]
6. Northup PG, McMahon MM, Ruhl AP, Altschuler SE, Volk-Bednarz A, Caldwell SH, Berg CL. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006; 101: 1524-1528; quiz 1680 [PMID: 16863556 DOI: 10.1111/ j.1572-0241.2006.00588.x]
7. Kim WR, Brown RS, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002; 36: 227-242 [PMID: 12085369 DOI: 10.1053/ jhep.2002.34734]
8. Wu H, Nguyen GC. Liver cirrhosis is associated with venous thromboembolism among hospitalized patients in a nation-wide US study. Clin Gastroenterol Hepatol 2010; 8: 800-805 [PMID: 20566312 DOI: 10.1016/j.cgh.2010.05.014]
9. Aldawood A, Arabi Y, Aljumah A, Alsaadi A, Rishu A, Aldorzi H, Alqahtani S, Alsultan M, Felemban A. The incidence of venous thromboembolism and practice of deep venous thrombosis prophylaxis in hospitalized cirrhotic patients. Thromb J 2011; 9: 1 [PMID: 21244669 DOI: 10.1186/1477-9560-9-1]
10. Ali M, Ananthakrishnan AN, McGinley EL, Saeian K. Deep vein thrombosis and pulmonary embolism in hospitalized patients with cirrhosis: a nationwide analysis. Dig Dis Sci 2011; 56: 2152-2159 [PMID: 21279685 DOI: 10.1007/ s10620-011-1582-5]
11. Walsh KA, Lewis DA, Clifford TM, Hundley JC, Gokun Y, Angulo P, Davis GA. Risk factors for venous thromboembolism in patients with chronic liver disease. Ann Pharmacother 2013; 47: 333-339 [PMID: 23482730 DOI: 10.1345/aph.1R496]
12. Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995; 21: 1238-1247 [PMID: 7737629]
13. Jairath V, Burroughs AK. Anticoagulation in patients with liver cirrhosis: complication or therapeutic opportunity? Gut 2013; 62: 479-482 [PMID: 23300140 DOI: 10.1136/ gutjnl-2012-303088]
14. Calvaruso V, Maimone S, Gatt A, Tuddenham E, Thursz M, Pinzani M, Burroughs AK. Coagulation and fibrosis in chronic liver disease. Gut 2008; 57: 1722-1727 [PMID: 19022928 DOI: 10.1136/gut.2008.150748]
15. Wright M, Goldin R, Hellier S, Knapp S, Frodsham A, Hennig B, Hill A, Apple R, Cheng S, Thomas H, Thursz M. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut 2003; 52: 1206-1210 [PMID: 12865283]
16. Villa E, Cammà C, Marietta M, Luongo M, Critelli R, Colopi S, Tata C, Zecchini R, Gitto S, Petta S, Lei B, Bernabucci V, Vukotic R, De Maria N, Schepis F, Karampatou A, Caporali C, Simoni L, Del Buono M, Zambotto B, Turola E, Fornaciari G, Schianchi S, Ferrari A, Valla D. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143: 1253-1260. e1-4 [PMID: 22819864 DOI: 10.1053/j.gastro.2012.07.018]
17. Kiladjian JJ, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S, Cazals-Hatem D, Plessier A, Garcia-Pagan JC, Darwish Murad S, Raffa S, Janssen HL, Gardin C, Cereja S, Tonetti C, Giraudier S, Condat B, Casadevall N, Fenaux P, Valla DC. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 2008; 111: 4922-4929 [PMID: 18250227 DOI: 10.1182/blood-2007-11-125328]
18. Michiels JJ, Commandeur S, Hoogenboom GJ, Wegman JJ, Scholten L, van Rijssel RH, De Raeve H. JAK2(V617F) positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature. Ann Hematol 2007; 86: 793-800 [PMID: 17687555 DOI: 10.1007/s00277-007-0351-1]
19. Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 2012; 120: 4921-4928 [PMID: 23043069 DOI: 10.1182/ blood-2011-09-376517]
20. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365: 147-156 [PMID: 21751907 DOI: 10.1056/NEJMra1011170]
21. Roberts LN, Patel RK, Arya R. Haemostasis and thrombosis in liver disease. Br J Haematol 2010; 148: 507-521 [PMID: 19995396 DOI: 10.1111/j.1365-2141.2009.08021.x]
22. Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, Leebeek FW. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44: 53-61 [PMID: 16799972 DOI: 10.1002/hep.21231]
23. Hollestelle MJ, Geertzen HG, Straatsburg IH, van Gulik TM, van Mourik JA. Factor VIII expression in liver disease. Thromb Haemost 2004; 91: 267-275 [PMID: 14961153 DOI: 10.1160/TH03-05-0310]
24. Lisman T, Bakhtiari K, Pereboom IT, Hendriks HG, Meijers JC, Porte RJ. Normal to increased thrombin generation in patients undergoing liver transplantation despite prolonged conventional coagulation tests. J Hepatol 2010; 52: 355-361 [PMID: 20132999 DOI: 10.1016/j.jhep.2009.12.001]
25. Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, Mannuccio Mannucci P. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41: 553-558 [PMID: 15726661 DOI: 10.1002/hep.20569]
26. Gatt A, Riddell A, Calvaruso V, Tuddenham EG, Makris M, Burroughs AK. Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J Thromb Haemost 2010; 8: 1994-2000 [PMID: 20546119 DOI: 10.1111/ j.1538-7836.2010.03937.x]
27. Tripodi A, Primignani M, Lemma L, Chantarangkul V, Dell' Era A, Iannuzzi F, Aghemo A, Mannucci PM. Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. Hepatology 2010; 52: 249-255 [PMID: 20578143 DOI: 10.1002/hep.23653]
28. Tripodi A, Primignani M, Chantarangkul V, Dell'Era A, Clerici M, de Franchis R, Colombo M, Mannucci PM. An imbalance of pro-vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009; 137: 2105-2111 [PMID: 19706293 DOI: 10.1053/j.gastro.2009.08.045]
29. Tripodi A, Primignani M, Lemma L, Chantarangkul V, Mannucci PM. Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. J Hepatol 2013; 59: 265-270 [PMID: 23583273 DOI: 10.1016/j.jhep.2013.03.036]
30. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160: 809-815 [PMID: 10737280]
31. García-Fuster MJ, Abdilla N, Fabiá MJ, Fernández C, Oliver V. [Venous thromboembolism and liver cirrhosis]. Rev Esp Enferm Dig 2008; 100: 259-262 [PMID: 18662076]
32. Dabbagh O, Oza A, Prakash S, Sunna R, Saettele TM. Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease. Chest 2010; 137: 1145-1149 [PMID: 20040609 DOI: 10.1378/ chest.09-2177]
33. Lesmana CR, Inggriani S, Cahyadinata L, Lesmana LA. Deep vein thrombosis in patients with advanced liver cirrhosis: a rare condition? Hepatol Int 2010; 4: 433-438 [PMID: 20305762 DOI: 10.1007/s12072-010-9166-6]
34. Anthony Lizarraga W, Dalia S, Reinert SE, Schiffman FJ. Venous thrombosis in patients with chronic liver disease. Blood Coagul Fibrinolysis 2010; 21: 431-435 [PMID: 20595823 DOI: 10.1097/MBC.0b013e328337b3ba]
35. Søgaard KK, Horváth-Puhó E, Grønbaek H, Jepsen P, Vilstrup H, Sørensen HT. Risk of venous thromboembolism in patients with liver disease: a nationwide populationbased case-control study. Am J Gastroenterol 2009; 104: 96-101 [PMID: 19098856 DOI: 10.1038/ajg.2008.34]
36. Huerta C, Johansson S, Wallander MA, García Rodríguez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 2007; 167: 935-943 [PMID: 17502535 DOI: 10.1001/archinte.167.9.935]
37. Saleh T, Matta F, Alali F, Stein PD. Venous thromboembolism with chronic liver disease. Am J Med 2011; 124: 64-68 [PMID: 21187186 DOI: 10.1016/j.amjmed.2010.08.014]
38. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H, Schulman S, Murad MH. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e195S-e226S [PMID: 22315261 DOI: 10.1378/chest.11-2296]
39. Runyon BA. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology 2013; 57: 1651-1653 [PMID: 23463403 DOI: 10.1002/hep.26359]
40. Gómez Cuervo C, Bisbal Pardo O, Pérez-Jacoiste Asín MA. Efficacy and safety of the use of heparin as thromboprophylaxis in patients with liver cirrhosis: a systematic review and meta-analysis. Thromb Res 2013; 132: 414-419 [PMID: 23993900 DOI: 10.1016/j.thromres.2013.08.001]
41. Vivarelli M, Zanello M, Zanfi C, Cucchetti A, Ravaioli M, Del Gaudio M, Cescon M, Lauro A, Montanari E, Grazi GL, Pinna AD. Prophylaxis for venous thromboembolism after resection of hepatocellular carcinoma on cirrhosis: is it necessary? World J Gastroenterol 2010; 16: 2146-2150 [PMID: 20440855]
42. Intagliata NM, Henry ZH, Shah N, Lisman T, Caldwell SH, Northup PG. Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding. Liver Int 2014; 34: 26-32 [PMID: 23758818 DOI: 10.1111/liv.12211]
43. Maruyama H, Takahashi M, Shimada T, Yokosuka O. Emergency anticoagulation treatment for cirrhosis patients with portal vein thrombosis and acute variceal bleeding. Scand J Gastroenterol 2012; 47: 686-691 [PMID: 22472055 DOI: 10.3109 /00365521.2012.674972]
44. Amitrano L, Guardascione MA, Menchise A, Martino R, Scaglione M, Giovine S, Romano L, Balzano A. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2010; 44: 448-451 [PMID: 19730112 DOI: 10.1097/MCG.0b013e3181b3ab44]
45. Delgado MG, Seijo S, Yepes I, Achécar L, Catalina MV, García-Criado A, Abraldes JG, de la Peña J, Bañares R, Albillos A, Bosch J, García-Pagán JC. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol 2012; 10: 776-783 [PMID: 22289875 DOI: 10.1016/j.cgh.2012.01.012]
46. Senzolo M, Sartori T, Rossetto V, Burra P, Cillo U, Boccagni P, Gasparini D, Miotto D, Simioni P, Tsochatzis E, A Burroughs K. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int 2012; 32: 919-927 [PMID: 22435854 DOI: 10.1111/ j.1478-3231.2012.02785.x]
47. Rodriguez-Castro KI, Simioni P, Burra P, Senzolo M. Anticoagulation for the treatment of thrombotic complications in patients with cirrhosis. Liver Int 2012; 32: 1465-1476 [PMID: 22734713 DOI: 10.1111/j.1478-3231.2012.02839.x]
48. Trotter JF, Olson J, Lefkowitz J, Smith AD, Arjal R, Kenison J. Changes in international normalized ratio (INR) and model for endstage liver disease (MELD) based on selection of clinical laboratory. Am J Transplant 2007; 7: 1624-1628 [PMID: 17511686 DOI: 10.1111/j.1600-6143.2007.01822.x]
49. Tripodi A, Caldwell SH, Hoffman M, Trotter JF, Sanyal AJ. Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Aliment Pharmacol Ther 2007; 26: 141-148 [PMID: 17593061 DOI: 10.1111/ j.1365-2036.2007.03369.x]
50. Tripodi A, Chantarangkul V, Primignani M, Fabris F, Dell' Era A, Sei C, Mannucci PM. The international normalized ratio calibrated for cirrhosis (INR(liver) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology 2007; 46: 520-527 [PMID: 17659574 DOI: 10.1002/hep.21732]
51. Mallett SV, Chowdary P, Burroughs AK. Clinical utility of viscoelastic tests of coagulation in patients with liver disease. Liver Int 2013; 33: 961-974 [PMID: 23638693 DOI: 10.1111/ liv.12158]
52. Bechmann LP, Sichau M, Wichert M, Gerken G, Kröger K, Hilgard P. Low-molecular-weight heparin in patients with advanced cirrhosis. Liver Int 2011; 31: 75-82 [PMID: 20958919 DOI: 10.1111/j.1478-3231.2010.02358.x]
53. Lisman T, Porte RJ. Towards a rational use of low-molecularweight heparin in patients with cirrhosis. Liver Int 2011; 31: 1063 [PMID: 21733099 DOI: 10.1111/j.1478-3231.2011.02489. x]
54. Senzolo M, Rodriguez-Castro KI, Rossetto V, Radu C, Gavasso S, Carraro P, Zerbinati P, Sartori MT, Simioni P. Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis. J Thromb Haemost 2012; 10: 1823-1829 [PMID: 22712870 DOI: 10.1111/j.1538-7836.2012.04824.x]
55. Lisman T, Kamphuisen PW, Northup PG, Porte RJ. Established and new-generation antithrombotic drugs in patients with cirrhosis-possibilities and caveats. J Hepatol 2013; 59: 358-366 [PMID: 23548197 DOI: 10.1016/j.jhep.2013.03.027]